Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Some nice deals happening:
https://endpts.com/bristol-myers-breaks-the-bank-on-eisais-folate-receptor-adc-drug-laying-out-more-than-3b-for-rights/
From my very very weak L2 knowledge it would appear that a buyer remains in the background, delayed trades in 500k region all morning and some disclosed on time, being held back for this order fill mugging the traders and panic sellers. It's certainly a time to HOLD. Jamesp looking forward to what you have to say and sharing that knowledge.
For those wanting confirmation that Sareums compounds target IL6, you want slide 9 of their interims:
http://www.sareum.com/files/1216/1969/5149/Sareum_Interims_Apr_2021_vF.pdf
Great image showing the timescale for the treatment:
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00139-9/fulltext
If you look back over the investor meet company presentations and Q&A you'll see the importance of the timing of treatment. A take-home treatment will come with specific measures, tested positive for COVID and showing heavy symptoms, this is the window we will target.
https://www.gov.uk/government/publications/covid-19-treatments-making-a-proposal-for-clinical-trials/guidance-making-a-proposal-for-covid-19-therapeutics-clinical-trials
This is the next process for us and I'm sure our UKRI investigator is on the ball. Will Sareum jump on what Tiziana have just done and RNS'd they are applying, throwing in the buzz word "Take home"... Personally I think not. Not Tim's style to RNS that.
It's telling everyone that TYK2 inhibition works for saving lives in severe covid patients, tofa is dirty hence the AE's reported - we are much cleaner for selectivity. It's the biggest confirmation yet really that TYK2 is the right target, the nature article and Kenneth B of course were correct.
Now time to get AGILE and the forward purchasing of compound by the government. All indications point to a billion mcap imo.
Here you go people:
https://www.nejm.org/doi/full/10.1056/NEJMoa2101643
Read and understand, those who know, well... we just know. Load up.
I've previousy referenced Kenneth Baillie who was involved in the nature article and made some clear signals on twitter, "That one change makes a difference to how much of the TYK2 gene you make. So we can ask, if you make more TYK2, are you more at risk?
The answer is yes. Less TYK2 is associated with lower risk. That suggests that a drug that inhibits TYK2 might make people less likely to develop life-threatening Covid-19. The good news is that we have a whole class of drugs that do this (JAK inhibitors)."
This article pulls it together nicely:
https://www.forbes.com/sites/judystone/2020/12/12/genes-may-hold-key-to-new-treatments-for-covid-19-infections/
UKRI sponsored the research into this study along with a number of others, for them to identify TYK2 as the gene to target and then not progress what is known as a second-generation TYK2 inhibitor, SDC-1801, is stupid. 1st generation which are approved have side effects based on their off-site targetting, namely JAK2/3. It is well researched that trying to selectively target TYK2 and JAK1 is an extremely difficult challenge, many have failed, and then others like BMS and Numbus have went for a different method of inhibition, but we'll not mention that again.
Tim and John are specialists in compound design, they have been working on this for nearly 10years, it's a slow process but they are perfectionists. Trust in their 10 years of painstaking research and design - you have an opportunity here to piggyback on some amazing work in compound design, take a step back, appreciate that and relax. Then understand that their business model is to on-licence at pre-clincial or early clinical - Tim has made comments previously that with the right compound they can license at any time - what more do you want in an investment, ah yes - to get in sub 1p.